Skip to content

Author

Xiao-Long Liu

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

XIAP inhibition augments personalized neoantigen vaccine-driven antitumor immunity in orthotopic hepatocellular carcinoma

Abstract Background Personalized neoantigen vaccines offer a rational immunotherapeutic strategy for hepatocellular carcinoma (HCC), but their efficacy is limited by insufficient tumor immunogenicity and an immunosuppressive tumor microenvironment. Tumor-intrinsic factors that constrain vaccine-induced immune responses...

Xiao-Yuan Zheng, Jun Fu, Geng Chen et al. · 0 citations
#protein folding Open access Oct 2026

Serum Protein Panel Facilitates Surgical Decision-Making for Barcelona Stage B Hepatocellular Carcinoma.

This serum proteomic-based prognostic model accurately predicts surgical outcomes for BCLC stage B HCC patients and outperforms clinical stratification by identifying low-risk patients who may benefit from surgery and has the potential to improve survival and quality of life.

Jin-Hua Wang, Liang-Liang Ren, Wan-Jun Zhang et al. · 0 citations
Open access Sep 2026

Glutamine sequestration promotes tumor growth and immune evasion through elevation of arginine methylation in hepatocellular carcinoma

Mechanisms underlying the immunosuppressive microenvironment in hepatocellular carcinoma (HCC) extend beyond immune checkpoints to include metabolic competition. Here, we identify a metabolic evasion pathway driven by SLC1A5 overexpression, which enables HCC cells to sequester glutamine from the tumor microenvironmen...

Jingjing Nian, Zi-Ran Wang, Shi-Yi Chen et al. · 0 citations
Open access Aug 2026

Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma

This urine-based model enables dynamic assessment of tumor burden and early recurrence detection, surpassing conventional serum biomarkers and providing a clinically actionable tool for personalized surveillance and therapeutic decision-making in HCC.

Xiao-Hua Xing, En Hu, Lei Song et al. · 0 citations
Open access Jul 2026

Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma

A biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC is developed and offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.

Yan-Bing Cao, Xin-Yi Lin, Bing-Chen Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.